For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

7177 products · Showing 6861–6880 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure
CAY10464Featured

CAY10464 (AHR antagonist 7; compound 4j) is a selective and high-affinity aryl hydrocarbon receptor (AhR) antagonist with a Ki of 1.4 nM.

CAY10464

Antiviral agent 52 (Compound 30) is a Chlorcyclizine (HY-112067) derivative that exhibits antiviral activity against hepatitic C virus (HCV) with an EC50 of 17 nM. Antiviral agent 52 reveals cytotoxicity in cell Huh7.5.1 with CC50 of 21.3 μM.

Antiviral agent 52
Psb-1491Featured

Highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B)

Psb-1491
ML315Featured

ML315 is a small molecule inhibitor of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases with IC50 of 68, 231, >10,000, 68, 282 and 1156 nM for CLK1/2/3/4 and DYRK1/2, respectively.

ML315

Antibacterial agent 125 is an antibacterial agent. Antibacterial agent 125 has a potent antimicrobial activity against clinically relevant Gram-positive pathogens with MIC50 values range from 0.25 - 8 μM. Antibacterial agent 125 can be used for the research of antimicrobial resistance.

Antibacterial agent 125
CB2R PAMFeatured

CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain.

CB2R PAM
WAY-301122Featured

cytotoxity (targeted to DNA topoisomerase II); anti-cancer activity; fungicides;

WAY-301122
WAY-328168Featured

antagonist of the NK3 receptor; altering the lifespan of a eukaryotic organism;

WAY-328168
WAY-328182Featured

restore E-cadherin expression in the SW620 colon adenocarcinoma cell line

WAY-328182

PRL-3 Inhibitor I is a potent PRL-3 inhibitor with an IC50 of 0.9 μM. PRL-3 Inhibitor I shows a reduced invasion in cell-based assay.

PRL-3 Inhibitor I
BTYNBFeatured

BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA with IC50 of 5 uM; has no effect on binding of PR to flPRE; destabilizes c-Myc mRNA, downregulates β-TrCP1 mRNA and reduces activation of NF-κB; also decreases oncogenic translation regulator eEF2 mRNA levels in cancer cells; potently inhibits proliferation of IMP1-containing ovarian cancer and melanoma cells with no effect in IMP1-negative cells.

BTYNB
AS-1269574Featured

AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays; displays no effect towards the other GPCRs, including the β-adrenergic and GLP-1 receptors; enhances insulin secretion in the mouse pancreatic β-cell line MIN-6 only under high-glucose (16.8mM) conditions; reduces blood glucose levels, does not affect fed and fasting plasma glucose levels in mice.

AS-1269574
UTL-5gFeatured

UTL-5g (GBL-5g) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity; lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice; a novel chemo- and radioprotective agent.

UTL-5g

FIPI (5-Fluoro-2-indolyl des-chlorohalopemide) hydrochloride, a derivative of Halopemide (HY-119093), is a phospholipase D (PLD) inhibitor with IC50s of approximately 25 nM and 20 nM for PLD1 and PLD2, respectively. FIPI hydrochloride inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis. FIPI hydrochloride has the potential for autoimmunity and cancer metastasis research.

FIPI hydrochloride
BD-1047Featured

BD-1047 is a potent, selecitve Sigma 1 receptor (σ1) antagonist with Ki of 0.93 nM; displays 50-fold weaker affinity for sigma 2 receptor, and 100-fold selectivity over opiate, phencyclidine, muscarinic, dopamine, adrenoceptor and 5-HT receptors; attenuates the dystonia induced by DTG and haloperidol in rats.

BD-1047

Page 344 of 359 · Browse all 7177 products

Jump to a product page

Featured literature product: HX1 · DCL0028

HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.

Read full formulation and performance →